Insiders' substantial share sale, especially by W. Staub and Constantinos Panagos, may worry shareholders. The lack of insider purchases over the past year could be a negative sign. Yet, high insider ownership might indicate well-aligned management incentives with shareholders.
The market's opinion of the business has improved over the past five years, likely due to consistent earnings growth. Despite recent sell-offs, if fundamentals suggest sustainable long-term growth, this could be a worthwhile opportunity.
IQVIA Holdings is currently undervalued and has a bright future. Its growth hasn't been fully factored into the share price. It may be a great time to increase holdings or enter the stock.
Insiders selling shares, even below current price, hint they may deem shares not cheap. Coupled with no insider buying, this may serve as a warning to potential investors. High insider ownership, but recent sale history of IQVIA Holdings insiders could raise concern.
Bio-Rad Laboratories is likely to maintain an 80% market share in digital PCR products due to extensive offering and embracing continuous investment. Bio-Techne's extensive product offerings and the growth of its analytical instruments business are likely to drive its growth. For IQVIA, sales growth is primarily expected from managing its existing backlog.
$艾昆緯(IQV.US)$this trade is the only one I am losing in my portfolio. the fake breakout trapped me, but it still haven’t trigger my stop loss at 240, I will wait and see what next!
$艾昆緯(IQV.US)$It has excellent earnings year over year. There is a strong uptrend since its inception. Consolidated for about a month before breaking resistance in August and using it as support, and consolidated for about another month continuing to use $254 as support. Looking to move higher as volume is coming in and testing $259 as support
艾昆緯股票討論區
2023Q1營收增長2.4%,營業利潤下滑2.8%,淨利潤下滑11%,高增速似乎要停止了。
目前市盈率38.9,市盈率TTM略增到39.9,考慮到近期增速下滑,可以多觀察幾個季度。
ready to move higher!
There is a strong uptrend since its inception.
Consolidated for about a month before breaking resistance in August and using it as support, and consolidated for about another month continuing to use $254 as support.
Looking to move higher as volume is coming in and testing $259 as support
暫無評論